Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03192202
Other study ID # AAAP4461
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date July 17, 2017
Est. completion date April 1, 2020

Study information

Verified date July 2023
Source Columbia University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators plan to investigate AFM13 and evaluate its ability to facilitate and redirect the Natural Killer (NK) cells in eliminating CD30-positive lymphoma targets in the skin and, by inference, other organs involved by the lymphoma.


Description:

This is an open label, Phase Ib/IIa study designed to evaluate the biologic activity of AFM13 in patients with relapsed or refractory CD30-positive lymphomas with cutaneous involvement. Primary cutaneous CD30-positive lymphoproliferative disorders (LPD) represent a spectrum from lymphomatoid papulosis (LyP), to primary cutaneous anaplastic large cell lymphoma (C-ALCL), to transformed mycosis fungoides (TMF). The most indolent form of primary cutaneous CD30-positive LPD is LyP, which is usually well controlled with low dose oral methotrexate, but control of the disease frequently requires life-long therapy. In contrast, TMF is an aggressive disease which does not have a standard of care, as patients are treated with various modalities of care with variable outcomes). The spectrum of other CD30-positive lymphomas with cutaneous presentation is very broad and involves systemic B and T cell lymphomas with various clinical behaviors. Redirecting Natural Killer (NK) cells towards these CD30-positive malignancies through direct engagement with AFM13 is expected to induce tumor cell killing through NK cell-mediated and T cell-mediated cytotoxicity (i.e., cytotoxic T lymphocytes (CTL)). The primary objective of this trial is to study the biologic and immunologic effects induced by the administration of various doses of AFM13, when given as a single agent.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date April 1, 2020
Est. primary completion date April 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 years - Histologically confirmed CD30-positive lymphoma with cutaneous involvement - Failure or intolerance to at least one prior therapy for the current disease - Presence of one or more cutaneous lesions (measuring at least 1 cm x 1 cm in size; if only one lesion is present it should be up to the investigator discretion to determine eligibility) - Eastern Cooperative Oncology Group (ECOG) performance status =2 - Adequate organ and marrow function - Platelets =50,000/µL - Absolute neutrophil count = 1,000/µL - Bilirubin < 1.5 x institutional upper limit of normal (ULN) or < 3 x ULN in patients with Gilbert's disease or liver involvement - Serum albumin = 2.0 g/dL - Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) =2.5 × institutional ULN or, in the case of liver involvement by the primary disease AST/ALT = 5 x ULN - Creatinine=1.5 x institutional ULN or estimated creatinine clearance of =45 mL/min by the Cockcroft-Gault equation or measured creatinine clearance >45 mL/min - Females of child bearing potential must have a negative serum pregnancy test with 7 days prior to first dose of treatment. Female patients of childbearing potential and all male partners must agree to use double barrier methods of contraception throughout the study period and for at least 30 days following investigational product discontinuation. - Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: - Any cancer-related therapy for the current disease within 2 weeks of screening (all supportive care measures are allowed) - Major surgery within 2 weeks prior to first dose of study drug - Evidence of active central nervous system (CNS) involvement - Requirement for systemic immunosuppressive therapy (e.g. Graft-versus-Host Disease (GVHD) therapy within 12 weeks before the first dose of study drug) - Uncontrolled concurrent serious illness. - Concurrent malignancy or history of a previous malignancy within 3 years prior to first dose of the current study, unless curatively resected basal, squamous cell carcinoma of the skin, or cervical carcinoma in situ. - Active infections including hepatitis B carrier status, hepatitis C virus (HCV) infection (patients must have a negative Hepatitis B and Hepatitis C viral load at screening) - Known HIV-positive status - Any significant medical conditions, laboratory abnormality, or psychiatric illness that would exclude the subject from participation or interfere with study treatment, monitoring and compliance such as: - unstable angina pectoris, symptomatic congestive heart failure (New York Heart Association (NYHA) III or IV), myocardial infarction = 6 months prior to first study drug, clinically significant and uncontrolled cardiac arrhythmia (e.g. atrial fibrillation/flutter ventricular cardiovascular physiology is allowed), cerebrovascular accidents = 6 months before study drug start - severely impaired lung function - Serious, systemic infection requiring treatment =7 days before the first dose of study drug - Any severe, uncontrolled disease or condition which in the investigator's opinion, may put the subject at significant risk, may confound the study results, or impact the subject's participation in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AFM13
AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed.

Locations

Country Name City State
United States Center for Lymphoid Malignancies New York New York

Sponsors (1)

Lead Sponsor Collaborator
Ahmed Sawas

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 Incidence of Treatment-Emergent Adverse Events [Safety and Toxicity] broken down by adverse event and CTCAE v4.0 grade of each event. Up to 2 years
Secondary Overall Response Rate (ORR) The sum of patients with partial responses and complete responses. Up to 2 years
See also
  Status Clinical Trial Phase
Terminated NCT03357224 - PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL) Phase 2
Completed NCT02567656 - Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma Phase 1
Completed NCT00051012 - Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Phase 4
Recruiting NCT03646422 - AEDV Registry of Primary Cutaneous Lymphoma
Terminated NCT03789864 - Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides N/A
Active, not recruiting NCT04998331 - A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin
Active, not recruiting NCT02953301 - Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) Phase 2
Completed NCT01486277 - A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma Phase 2
Completed NCT01433731 - Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL) Phase 1
Completed NCT05137847 - A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
Active, not recruiting NCT03902184 - IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma Phase 2
Completed NCT00896493 - Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma Phase 2
Completed NCT00211198 - Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) Phase 4
Terminated NCT03601819 - Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders Phase 1
Withdrawn NCT03742804 - Study Of Intratumoral G100 In Cutaneous T Cell Lymphoma Phase 2
Completed NCT02836886 - VircapSeq Virus Detection in Sézary Syndrome
Completed NCT00050999 - Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients Phase 4
Terminated NCT02323659 - Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas Phase 4
Recruiting NCT02840747 - Tissue Repository: CTCL Collection Protocol
Terminated NCT02811783 - Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL Phase 3